

06/12/01

PTO  
U.S. Patent and Trademark Office  
Washington, D.C. 20231

06-13101

A

UTILITY PATENT APPLICATION  
TRANSMITTALAttorney Docket No.  
First Named InventorP50186-2XC2  
Holmes et al.

New nonprovisional applications under 37 CFR 1.53(b)

## "EXPRESS MAIL CERTIFICATE"

"EXPRESS MAIL" MAILING LABEL NUMBER EL 737870106 US DATE OF DEPOSIT: JUNE 12, 2001

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to:  
The Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231NAME OF PERSON MAILING PAPER OR FEE  
(TYPE OR PRINT) Sabrina Smith

SIGNATURE

Sabrina SmithU.S. Patent and Trademark Office  
09/879461  
06/12/01

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570 <input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) (Submit an original, and a duplicate for fee processing)	7. <input checked="" type="checkbox"/> The Title of the Invention: RECOMBINANT IL4 ANTIBODIES USEFUL IN TREATMENT OF IL4 MEDIATED DISORDERS
2. <input checked="" type="checkbox"/> The total fee is calculated as shown below: Basic Filing fee \$710.00 Total Claims 14 - 20 = 6 x \$18 \$108.00 Independent Claims 3 - 3 = 0 x \$80 \$ 0.00 <input type="checkbox"/> Multiple Dependent Claim present. \$270 <b>TOTAL FILING FEE \$818.00</b> <input checked="" type="checkbox"/> Cancel in this application original claims 10 to 13 and 19-38 of the prior application before calculating the filing fee. <input checked="" type="checkbox"/> Charge \$818.00 to the above indicated Deposit Account.	8. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies d. <input type="checkbox"/> Use the identical computer-readable form filed in Application No. 08/612,929, filed 30 April 1996 as the computer-readable form for the instant application. (37 CFR 1.821(e))
3a. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] 81 3b. <input checked="" type="checkbox"/> Abstract on a separate sheet [Total Pages] 1	9. <input type="checkbox"/> Information Disclosure Statement (IDS) b. <input checked="" type="checkbox"/> PTO-1449 c. <input type="checkbox"/> Copies of all IDS Citations
4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] 11	10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
5. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] 4 a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17a completed) c. <input type="checkbox"/> Unsigned Declaration [Note Box 6 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	11. <input checked="" type="checkbox"/> Prior Application is Assigned to: SmithKline Beecham p.l.c. and SmithKline Beecham Corporation (for continuation/divisional with Box 17a completed)
6. <input checked="" type="checkbox"/> Incorporation By Reference (useable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	12. <input checked="" type="checkbox"/> Preliminary Amendment [Total Pages] 2
17. <input checked="" type="checkbox"/> Priority Information, check appropriate box and supply the requisite information	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
a. The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: 09/426,814 filed October 22, 1999.	14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)
b. <input type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. filed	15. <input checked="" type="checkbox"/> Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. 09/426,814 filed October 22, 1999. A PTO-1449 listing the references is enclosed.
c. <input checked="" type="checkbox"/> Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) (see Preliminary Amendment)	16. <input type="checkbox"/> Other:
18. CORRESPONDENCE ADDRESS	
19. RESPECTFULLY SUBMITTED.	
Address GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Telephone (610) 270-5096 Fax (610) 270-5090	Signature Name Kirk Baumeister Registration No. 33,833